Evidence map›Paper›PMID 42454104›Full record

ArticleComputational and structural biotechnology journal2026

MiracleNet: A Biologically Interpretable Machine Learning Model for Resected Non-small-cell Lung Cancer.

Rashika Jakhmola, David A Selby, Mert Cihan, Dusan Prascevic, Elisabetta Petracci, Paola Ulivi, Enriqueta Felip, Rocío Caro-Consuegra, Franco Stella, Piergiorgio Solli and 7 more

Abstract read
In one paragraph

Article in Computational and structural biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Rashika JakhmolaDepartment of Dermatology, University Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany.ORCID https://orcid.org/0009-0006-1778-1466
David A SelbyData Science & Its Applications, German Research Center for Artificial Intelligence (DFKI), Kaiserslautern, Germany.
Mert CihanFaculty of Biology, Johannes Gutenberg University, Mainz, Germany.
Dusan PrascevicCenter for Scalable Data Analytics and Artificial Intelligence (ScaDS.AI) Dresden/Leipzig, Leipzig University, Leipzig, Germany.ORCID https://orcid.org/0009-0002-5326-4950
Elisabetta PetracciUnit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Paola UliviBiosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, FC, Italy.
Enriqueta FelipThoracic Tumors Group, Vall d'Hebron Institut d'Oncologia (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Rocío Caro-ConsuegraThoracic Tumors Group, Vall d'Hebron Institut d'Oncologia (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.ORCID https://orcid.org/0009-0003-8562-6132
Franco StellaThoracic Surgery Department, AUSL Romagna, Forlì, Italy.
Piergiorgio SolliThoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID https://orcid.org/0000-0002-4890-2578
Desideria ArgnaniThoracic Surgery Department, AUSL Romagna, Ravenna, Italy.
Milena UrbiniBiosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, FC, Italy.
Johannes U MayerDepartment of Dermatology, University Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany.ORCID https://orcid.org/0000-0001-6225-7803
Sebastian J VollmerData Science & Its Applications, German Research Center for Artificial Intelligence (DFKI), Kaiserslautern, Germany.
Christian MartinCenter for Scalable Data Analytics and Artificial Intelligence (ScaDS.AI) Dresden/Leipzig, Leipzig University, Leipzig, Germany.ORCID https://orcid.org/0000-0002-3128-630X
Jan EwaldCenter for Scalable Data Analytics and Artificial Intelligence (ScaDS.AI) Dresden/Leipzig, Leipzig University, Leipzig, Germany.ORCID https://orcid.org/0000-0002-9415-2317
Maximilian SprangDepartment of Dermatology, University Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany.ORCID https://orcid.org/0000-0002-8438-4747

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer remains one of the leading causes of cancer-related mortality worldwide. Accurate prediction of relapse is notoriously difficult, posing substantial challenges to patient care and necessitating advanced tools to improve prognostic outcomes. MicroRNA (miRNA) expression profiles hold promise as biomarkers for predicting relapse, yet existing predictive models lack interpretability or sufficient predictive performance. Biologically informed neural networks have emerged as a modeling approach incorporating biological interpretability and predictive accuracy. Here, we introduce MiracleNet, to our knowledge the first visible neural network in which sparse connectivity is structured by the miRNA → target gene → pathway hierarchy for disease-free survival prediction from circulating miRNA in non-small-cell lung cancer and the first to expose interpretable importances jointly at all 3 biological layers, with nodes connected by prior knowledge about miRNA targets and related biological pathways. Our model, which also integrates clinical data, achieves a maximum concordance index of 0.76, demonstrates improved generalization over unconstrained neural networks of the same dimensionality (including both dense and sparse architectures lacking biological knowledge), and provides explicit biological interpretability. Our model also highlights several important biomarkers in the form of predictive miRNAs and connected biological pathways. We additionally evaluate MiracleNet under a nested repeated 80/20 protocol, augmented with patient sex and tumor stage as clinical covariates and combined across circulating free and extracellular-vesicle-associated miRNAs through early and intermediate fusion; these analyses are reported as separate sections.

Identifiers

PMID42454104
PMCPMC13365569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.